Scientific Program Manager, The Biomarkers Consortium, Foundation for the National Institutes of Health, 2007-2014

  • I developed projects to meet unmet medical needs by finding and clinically validating biomarkers, setting up public-private partnerships and project teams to carry out the projects in the oncology area. We worked very closely with the NIH and FDA and scientists in industry and academic centers.
  • My biggest projects were the I-SPY 2 TRIAL, An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy, and LungMAP, the Lung Cancer Master Protocol.

NIH, Office of Extramural Programs, Office of Extramural Research, 2007

Scientific Manager, Genentech, 2005-2006, Scientific Manager, Mouse Genetics Research

Associate Professor of Microbiology, and Biochemistry and Molecular Genetics, University of Virginia School of Medicine, through 2004

  • Directed a research laboratory, obtaining grants, writing papers, training students.
  • Directed a Transgenic/Knockout Core laboratory, obtaining funding, directing technical staff, managing projects, liaison with the Cancer Center.
  • Taught medical and graduate students. Subjects were medical microbiology and mammalian genetics.

Publications, peer reviewed:

  1. Peden, K.W.C., J.M. Pipas, H. Pearson-White, and D. Nathans, “Isolation of mutants of an animal virus in bacteria,” Science 209:1392-1396, 1980.
  2. Hallauer, P.L., K.E.M. Hastings, A.S. Baldwin, H. Pearson-White, P.A. Merrifield, and C.P. Emerson, Jr., “Closely related a-tropomyosin mRNAs in quail fibroblasts and skeletal muscle cells,” J. Biol. Chem., 262:3590-3596, 1987.
  3. Pearson-White, S.H. and C.P. Emerson, Jr., “A novel hybrid a-tropomyosin in fibroblasts is produced by alternative splicing of transcripts from the skeletal muscle a-tropomyosin gene,” Biol. Chem., 262:15998-16010, 1987.
  4. Pinney, D.F., H. Pearson-White, S.F. Konieczny, K.E. Latham, and C.P. Emerson, Jr., “Myogenic lineage determination and differentiation: Evidence for a regulatory gene pathway,” Cell 53:781-793, 1988.
  5. Pearson-White, S.H. “Human MyoD:cDNA and deduced amino acid sequence,” Nucleic Acids Research, 19: 1148, 1991.
  6. Dekel, I., Y. Magal, Pearson-White, C.P. Emerson, Jr., and M. Shani, “Conditional conversion of ES cells to skeletal muscle by an exogenous MyoD1 gene,”The New Biologist, 4:217-224, 1992.
  7. Shani, M., A. Faerman, C.P. Emerson, Jr., Pearson-White, I. Dekel, and Y. Magal. “The consequences of a constitutive expression of MyoD1 in ES cells and mouse embryos,” Symposia of the Society for Experimental Biology, 46:19-36, 1992.
  8. Stewart, F.M., R.B. Crittenden, P.A. Lowry, Pearson-White, and P. J. Quesenberry, “Long-term engraftment of normal and post-5-Fluorouracil murine marrow into normal nonmyeloablated mice,” Blood 81:2566-2571, 1993.
  9. Faerman, A., Pearson-White, C. Emerson, and M. Shani, “Ectopic expression of MyoD1 in mice causes prenatal lethalities,” Developmental Dynamics 196: 165-173, 1993.
  10. Pearson-White, S., “SnoI, a novel alternatively spliced isoform of the ski proto-oncogene homolog, sno,” Nucleic Acids Research, 21:4632-4638, 1993.
  11. Pearson-White, S., D. Deacon, R. Crittenden, G. Brady, N.N. Iscove, and P.J. Quesenberry, “The ski/sno proto-oncogene family in hematopoietic development,” Blood, 86:2146-2155, 1995.
  12. Quesenberry, P. J., N. N. Iscove, C. Cooper, G. Brady, P. E. Newburger, G. S. Stein, J. S. Stein, G. P. V. Reddy, and Pearson-White, “Expression of basic helix-loop-helix transcription factors in explant hematopoietic progenitors,” J. Cell. Biochem., 61:478-488, 1996.
  13. Pearson-White, S. and R. Crittenden, “Proto-oncogene sno expression, alternative isoforms, and immediate early serum response,” Nucleic Acids Research, 25:2930-2937, 1997. and
  14. Pearson-White, S., “Genotyping DMDmdx3Cv and DMDmdx4Cv mutations in mice using PCR”, Neuromuscular Disorders, 12:366-370 (2002).
  15. Lijun Xia, Markus Sperandio, Tadayuki Yago, Michael McDaniel, Richard D. Cummings, Sonia Pearson-White, Klaus Ley, and Rodger P. McEver, “Neutrophils from P-selectin Glycoprotein Ligand-1-deficient Mice Roll Weakly on P-selectin and Tether Poorly to E-selectin in Flow”, Clinical Investigation 109:939-950 (2002).
  16. Pearson-White, S. and McDuffie, M., “Defective T cell Activation is Associated with Augmented TGF-beta Sensitivity in Mice with Mutations in the Sno Gene”, Molecular and Cellular Biology 23:5446-5459 (2003). and
  17. Kharel Y, Lee S, Snyder AH, Sheasley-O’neill SL, Morris MA, Setiady Y, Zhu R, Zigler MA, Burcin TL, Ley K, Tung KS, Engelhard VH, Macdonald TL, Pearson-White S, Lynch KR. “Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.” Biol Chem. 2005 Nov 4;280(44):36865-72. (2005).
  18. Zhu, Q, Pearson-White, S., and Luo, K. “Requirement for the SnoN oncoprotein in transforming growth factor beta-induced oncogenic transformation of fibroblast cells”, Molecular and Cellular Biology Dec;25(24):10731-44 (2005). and
  19. Parkinson DR, Dracopoli N, Gumbs Petty B, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JS, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ., “Considerations in the development of circulating tumor cell technology for clinical use.” J Transl Med. 2012 Jul 2;10(1):138. [Epub ahead of print] and
  20. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Jo Chien A, Demichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van’t Veer L, Berry DA, Esserman L., Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development, J Clin Oncol. 30(36): 4584-4586 (2012). and

Leave a Reply

* required fields